|
1) Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology. 2000; 32: 11-6
|
|
|
|
2) Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology. 2008; 135: 438-50
|
|
|
|
|
|
3) Souza BS, Nogueira RC, de Oliveira SA, et al. Current status of stem cell therapy for liver diseases. Cell Transplant. 2009; 18: 1261-79
|
|
|
|
|
|
4) Gilchrist ES, Plevris JN. Bone marrow-derived stem cells in liver repair: 10 years down the line. Liver Transpl. 2010; 16: 118-29
|
|
|
|
|
|
5) Stutchfield BM, Forbes SJ, Wigmore SJ. Prospects for stem cell transplantation in the treatment of hepatic disease. Liver Transpl. 2010; 16: 827-36
|
|
|
|
|
|
6) Gordon MY, Levicar N, Pai M, et al. Characterization and clinical application of human CD34＋ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006; 24: 1822-30
|
|
|
|
|
|
7) Spahr L, Lambert JF, Rubbia-Brandt L, et al. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology. 2008; 48: 221-9
|
|
|
|
|
|
8) Pai M, Zacharoulis D, Milicevic MN, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34＋ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 2008; 103: 1952-8
|
|
|
|
|
|
9) Han Y, Yan L, Han G, et al. Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-stimulating factor mobilization therapy. Cytotherapy. 2008; 10: 390-6
|
|
|
|
|
|
10) Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet. 1999; 353: 555
|
|
|
|
|
|
11) am Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133＋ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005; 23: 463-70
|
|
|
|
|
|
12) Furst G, Schulte am Esch J, Poll LW, et al. Portal vein embolization and autologous CD133＋ bone marrow stem cells for liver regeneration: initial experience. Radiology. 2007; 243: 171-9
|
|
|
|
|
|
13) Terai S, Sakaida I, Yamamoto N, et al. An in vivo model for minitoring the transdifferentiation of bone marrow cells into functinal hepatocytes. J Biochem. 2003; 134: 551-8
|
|
|
|
|
14) Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 2004; 40: 1304-11
|
|
|
|
|
|
15) Terai S, Sakaida I, Nishina H, et al. Lesson from the GFP/CCl4 model-translational research project: the development of cell therapy using autologous bone marrow cells in patients with liver cirrhosis. J Hepatobiliary Pancreat Surg. 2005; 12: 203-7
|
|
|
|
|
|
16) Takami T, Terai S, Sakaida I. Novel findings for the development of drug therapy for various liver diseases: Current state and future prospects for our liver regeneration therapy using autologous bone marrow cells for decompensated liver cirrhosis patients. J Pharmacol Sci. 2011; 115: 274-8
|
|
|
|
|
|
17) Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006; 24: 2292-8
|
|
|
|
|
|
18) Terai S, Sakaida I. Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients. Hepatol Res. 2008; 38 (s1The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan): S72-S5
|
|
|
|
|
|
19) Terai S, Sakaida I. Autologous bone marrow cell infusion therapy for liver cirrhosis patients. J Hepatobiliary Pancreat Sci. 2011; 18: 23-5
|
|
|
|
|
|
20) Kim JK, Park YN, Kim JS, et al. Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis. Cell Transplant. 2010; 19: 1237-46
|
|
|
|
|
|
21) Saito T, Okumoto K, Haga H, et al. Potential therapeutic application of intravenous autologous bone marrow infusion in patients with alcoholic liver cirrhosis. Stem Cells Dev. 2011 May 11. [Epub ahead of print]
|
|
|
|
|
|
22) Ishikawa T, Terai S, Urata Y, et al. Fibroblast growth factor 2 facilitates the differentiation of transplanted bone marrow cells into hepatocytes. Cell Tissue Res. 2006; 323: 221-31
|
|
|
|
|
|
23) Omori K, Terai S, Ishikawa T, et al. Molecular signature associated with plasticity of bone marrow cell under persistent liver damage by self-organizing-map-based gene expression. FEBS Lett. 2004; 578(1-2): 10-20
|
|
|
|
|
|
24) Yokoyama Y, Terai S, Ishikawa T, et al. Proteomic analysis of serum marker proteins in recipient mice with liver cirrhosis after bone marrow cell transplantation. Proteomics. 2006; 6: 2564-70
|
|
|
|
|
|
25) Lyra AC, Soares MB, da Silva LF, et al. Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J Gastroenterol. 2007; 13: 1067-73
|
|
|
|
|
|
26) Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007; 10: 459-66
|
|
|
|
|
|
27) Kharaziha P, Hellstrom PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009; 21: 1199-205
|
|
|
|
|
|
28) Peng L, Xie DY, Lin BL, et al. Autologous bone mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes. Hepatology. 2011 May 23. [Epub ahead of print]
|
|
|
|
|
|
29) Mohamadnejad M, Namiri M, Bagheri M, et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol. 2007; 13: 3359-63
|
|
|
|
|